In short
This article discusses the clinical trials of ATL1102, a drug being studied for the treatment of Duchenne Muscular Dystrophy (DMD) in non-ambulatory patients. ATL1102 is a 2'-O-(2-Methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA. The trials aim to evaluate the drug's efficacy, safety, and pharmacokinetic profile in improving upper limb muscle function and other aspects of DMD patients' health.
At a glance
- Drug Name
- ATL1102 (2'-O-(2-Methoxyethyl) Phosphorothioate Antisense Oligonucleotide Targeting CD49d RNA)
- Condition
- Duchenne Muscular Dystrophy (DMD)
- Trial Phase
- Phase II
- Study Design
- Multicentre, randomised, double-blind, placebo-controlled with open label extension
- Primary Objectives
- Evaluate effect on upper limb muscle function, safety, and tolerability
- Key Measurements
- Performance of Upper Limb Module (PUL 2.0), muscle strength, respiratory function, quality of life
- Administration
- Subcutaneous injection, once weekly
- Participant Age
- 10 to less than 18 years
- Key Inclusion Criteria
- Non-ambulatory DMD patients, minimum 25 kg body weight, stable corticosteroid therapy
- Duration
- 49 weeks (25 weeks blinded phase + 24 weeks open label extension)
What is ATL1102?
ATL1102 is a new medication being studied for the treatment of Duchenne Muscular Dystrophy (DMD). Its full scientific name is 2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA. This long name describes its chemical structure and how it works in the body.
How Does ATL1102 Work?
ATL1102 is a type of drug called an antisense oligonucleotide. This means it's designed to interfere with specific genetic messages in the body. In this case, it targets a protein called CD49d, which is involved in inflammation. By reducing CD49d, ATL1102 may help slow down the progression of muscle damage in DMD.
Target Condition: Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is a genetic disorder that causes progressive muscle weakness and loss of muscle mass. It primarily affects boys and typically becomes apparent in early childhood. DMD is caused by a mutation in the gene that produces dystrophin, a protein essential for maintaining muscle integrity.
Clinical Trial Overview
A clinical trial is currently underway to test ATL1102 in patients with DMD. This trial is designed to evaluate how well the drug works and how safe it is. Here are some key points about the study:
- It's a Phase II trial, which means it's testing the drug in a larger group of patients after initial safety studies.
- The study is randomized (patients are assigned to different groups by chance) and double-blind (neither the patients nor the doctors know who is getting the real drug or a placebo).
- It includes an open-label extension phase where all participants receive the active drug.
- The drug is given by subcutaneous injection (an injection under the skin) once a week.
Eligibility Criteria
To participate in this study, patients must meet certain criteria. Some key requirements include:
- Male patients aged 10 to less than 18 years
- Confirmed diagnosis of DMD through genetic testing
- Non-ambulatory (unable to walk 10 meters without assistance)
- Body weight of at least 25 kg
- Adequate heart and lung function
There are also several exclusion criteria, such as recent use of certain medications or participation in other clinical trials.
Study Objectives
The main goals of this study are:
- To evaluate how ATL1102 affects upper limb muscle function in non-ambulant DMD patients
- To assess the safety and tolerability of ATL1102
- To study how the drug moves through the body (pharmacokinetics)
- To measure effects on muscle strength, respiratory function, and quality of life
Potential Benefits
If successful, ATL1102 could potentially:
- Slow down the progression of muscle weakness in DMD patients
- Improve or maintain upper limb function
- Enhance quality of life for patients with DMD
Safety Considerations
As with any clinical trial, patient safety is a top priority. The study includes several measures to monitor safety:
- Regular medical check-ups and laboratory tests
- Monitoring of heart and lung function
- A safety monitoring plan and stopping rules to quickly address any concerns
- Careful tracking of any side effects or adverse events
It's important to note that while ATL1102 shows promise, it is still an experimental treatment. More research is needed to fully understand its effectiveness and safety profile in treating Duchenne Muscular Dystrophy.